Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ
Market Cap
$2.69B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
618 of 951
Rank in Industry
340 of 544
Largest Insider Buys in Sector
CPRX Stock Price History Chart
CPRX Stock Performance
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Activity of Catalyst Pharmaceuticals, Inc.
Over the last 12 months, insiders at Catalyst Pharmaceuticals, Inc. have bought $0 and sold $29.48M worth of Catalyst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Catalyst Pharmaceuticals, Inc. have bought $130,960 and sold $16.03M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $89,100 was made by MCENANY PATRICK J (President and CEO) on 2020‑09‑30.
List of Insider Buy and Sell Transactions, Catalyst Pharmaceuticals, Inc.
| 2024-12-10 | Sale | Chief Op. & Scientific Officer | 50,000 0.0417% | $21.93 | $1.1M | -2.67% | ||
| 2024-11-27 | Sale | Chief Med. & Reg. Officer | 12,000 0.0102% | $22.72 | $272,654 | -2.82% | ||
| 2024-11-27 | Sale | director | 17,500 0.0144% | $22.00 | $385,000 | -2.82% | ||
| 2024-11-26 | Sale | Chief Compliance/Legal Officer | 13,256 0.011% | $21.63 | $286,704 | -0.93% | ||
| 2024-11-20 | Sale | Chairman of Board of Directors | 72,500 0.0612% | $21.29 | $1.54M | +2.62% | ||
| 2024-11-20 | Sale | Chief Med. & Reg. Officer | 38,000 0.032% | $21.20 | $805,562 | +2.62% | ||
| 2024-11-19 | Sale | Chairman of Board of Directors | 98,345 0.0823% | $21.19 | $2.08M | -0.07% | ||
| 2024-11-14 | Sale | Chairman of Board of Directors | 44,655 0.0376% | $21.75 | $971,336 | -5.30% | ||
| 2024-11-13 | Sale | Chairman of Board of Directors | 92,500 0.0776% | $22.98 | $2.13M | -4.93% | ||
| 2024-11-12 | Sale | Chairman of Board of Directors | 262,000 0.221% | $23.26 | $6.09M | -5.82% | ||
| 2024-11-11 | Sale | Chairman of Board of Directors | 230,000 0.1936% | $23.55 | $5.42M | -7.44% | ||
| 2024-08-21 | Sale | director | 15,000 0.0124% | $20.10 | $301,455 | +3.47% | ||
| 2024-08-20 | Sale | Chief Op. & Scientific Officer | 150,000 0.1243% | $20.35 | $3.05M | +2.32% | ||
| 2024-08-09 | Sale | Chief Med. & Reg. Officer | 100,000 0.0826% | $18.04 | $1.8M | +14.45% | ||
| 2024-08-09 | Sale | Chief Commercial Officer | 36,058 0.0304% | $18.42 | $664,310 | +14.45% | ||
| 2024-06-07 | Sale | Chief Commercial Officer | 7,541 0.0066% | $16.07 | $121,184 | +30.95% | ||
| 2024-06-05 | Sale | Chief Med. & Reg. Officer | 80,000 0.0671% | $16.16 | $1.29M | +25.40% | ||
| 2024-06-04 | Sale | President and CEO | 17,323 0.0146% | $15.97 | $276,735 | +27.43% | ||
| 2024-06-03 | Sale | director | 5,333 0.0045% | $16.30 | $86,949 | +26.30% | ||
| 2024-04-08 | Sale | director | 25,000 0.0214% | $15.68 | $392,000 | +27.87% |
Insider Historical Profitability
41.2%
| MCENANY PATRICK J | Chairman of Board of Directors | 4478169 3.7546% | $22.55 | 36 | 14 | +56.01% |
| Miller Steve | Chief Op. & Scientific Officer | 686996 0.576% | $22.55 | 3 | 9 | +36.11% |
| Tierney David S | director | 348874 0.2925% | $22.55 | 3 | 7 | +8.21% |
| Daly Richard J | President and CEO | 234824 0.1969% | $22.55 | 0 | 1 | |
| Elsbernd Brian | Chief Compliance/Legal Officer | 165377 0.1387% | $22.55 | 0 | 3 | |
| INGENITO GARY | Chief Med. & Reg. Officer | 51391 0.0431% | $22.55 | 0 | 13 | |
| Del Carmen Jeffrey | Chief Commercial Officer | 12369 0.0104% | $22.55 | 0 | 5 | |
| Harper Molly | director | 0 0% | $22.55 | 0 | 3 | |
| BIOMARIN PHARMACEUTICAL INC | 10 percent owner | 6666667 5.5894% | $22.55 | 1 | 0 | |
| HUCKEL HUBERT E MD | director | 1304134 1.0934% | $22.55 | 5 | 0 | |
| O'Keeffe Charles B | director | 565057 0.4738% | $22.55 | 32 | 1 | +34.04% |
| WALLACE MILTON J | director | 539184 0.4521% | $22.55 | 11 | 0 | +22.92% |
| DENKHAUS DONALD A | director | 277666 0.2328% | $22.55 | 9 | 2 | +38.42% |
| COELHO PHILIP H | director | 149553 0.1254% | $22.55 | 30 | 9 | +54.72% |
| Winship M Douglas | VP, Regulatory Operations | 74131 0.0622% | $22.55 | 2 | 1 | |
| GRANDE ALICIA | VP, Treasurer and CFO | 50557 0.0424% | $22.55 | 6 | 14 | +54.75% |
| MUTH DAVID D | EVP, Chief Commercial Officer | 44700 0.0375% | $22.55 | 4 | 0 | +27.84% |
| Weinstein Jack | V.P., Treasurer & CFO | 14493 0.0122% | $22.55 | 7 | 0 | +25.24% |
| Sundaram Preethi | Chief Strategy Officer | 0 0% | $22.55 | 0 | 2 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $282.66M | 15.01 | 17.73M | +12.07% | +$30.45M | 0.01 | |
| Deerfield Management | $145.55M | 7.73 | 9.13M | +2.72% | +$3.86M | 0.36 | |
| State Street | $129.96M | 6.9 | 8.15M | +20.12% | +$21.77M | 0.01 | |
| The Vanguard Group | $127.21M | 6.76 | 7.98M | +12.08% | +$13.71M | <0.01 | |
| Dimensional Fund Advisors | $43.64M | 2.32 | 2.74M | +5.22% | +$2.17M | 0.01 | |
| Janus Henderson | $43.45M | 2.31 | 2.73M | +139.45% | +$25.3M | 0.02 | |
| Geode Capital Management | $39.99M | 2.12 | 2.51M | +13.99% | +$4.91M | <0.01 | |
| ROYCE & ASSOCIATES INC | $33.22M | 1.76 | 2.08M | +19.56% | +$5.43M | 0.3 | |
| Renaissance Technologies | $30.1M | 1.6 | 1.89M | +18.22% | +$4.64M | 0.05 | |
| Morgan Stanley | $28.67M | 1.52 | 1.8M | -8.29% | -$2.59M | <0.01 | |
| Marshall Wace | $26.84M | 1.43 | 1.68M | New | +$26.84M | 0.03 | |
| Boston Partners | $23.79M | 1.28 | 1.51M | -2.25% | -$548,338.42 | 0.03 | |
| Northern Trust | $22.79M | 1.21 | 1.43M | +0.78% | +$175,451.58 | <0.01 | |
| Jacobs Levy Equity Management | $20.02M | 1.06 | 1.26M | -2.38% | -$487,955.28 | 0.07 | |
| T. Rowe Price | $19.44M | 1.03 | 1.22M | +1.91% | +$364,416.09 | <0.01 | |
| Citadel Advisors LLC | $17.83M | 0.95 | 1.12M | +119.26% | +$9.7M | 0.01 | |
| Voloridge Investment Management, LLC | $17.26M | 0.92 | 1.08M | +72.08% | +$7.23M | 0.06 | |
| Charles Schwab | $17.14M | 0.91 | 1.08M | +12.47% | +$1.9M | <0.01 | |
| Kennedy Capital Management Inc | $16.92M | 0.9 | 1.06M | +101.12% | +$8.51M | 0.36 | |
| Opaleye Management Inc | $16.01M | 0.85 | 1M | -20.11% | -$4.03M | 3.54 | |
| Goldman Sachs | $15.96M | 0.85 | 1M | +4.47% | +$683,315.91 | <0.01 | |
| Invesco | $15.85M | 0.84 | 994,058 | +8.09% | +$1.19M | <0.01 | |
| LSV Asset Management | $14.28M | 0.76 | 896,000 | -27.2% | -$5.34M | 0.03 | |
| BNY Mellon | $13.03M | 0.69 | 817,455 | +3.52% | +$443,673.87 | <0.01 | |
| Jupiter Fund Management | $12.9M | 0.69 | 809,360 | -4.1% | -$551,061.77 | 0.04 | |
| Mesirow Institutional Investment Management Inc | $11.46M | 0.61 | 719,104 | New | +$11.46M | 1.02 | |
| Deutsche Bank | $9.98M | 0.53 | 626,253 | +1.16% | +$114,241.99 | 0.01 | |
| Man Group Plc | $9.87M | 0.52 | 619,411 | -3.85% | -$395,391.73 | 0.02 | |
| Nuveen | $9.09M | 0.48 | 570,519 | +112.32% | +$4.81M | <0.01 | |
| Ikarian Capital LLC | $8.26M | 0.44 | 518,386 | +2.48% | +$199,632.56 | 1.14 | |
| Woodline Partners LP | $8.03M | 0.43 | 503,758 | New | +$8.03M | 0.07 | |
| Altium Capital Management Lp | $7.97M | 0.42 | 500,000 | +29.87% | +$1.83M | 0.94 | |
| Citigroup | $7.82M | 0.42 | 490,704 | +138.39% | +$4.54M | 0.01 | |
| Rafferty Asset Management Llc | $7.76M | 0.41 | 486,774 | +38.22% | +$2.15M | 0.02 | |
| JPMorgan Chase | $7.59M | 0.4 | 476,420 | +9.12% | +$634,603.30 | <0.01 | |
| Oberweis Asset Management Inc | $7.31M | 0.39 | 458,400 | +31.5% | +$1.75M | 0.53 | |
| Gables Capital Management Inc | $6.96M | 0.37 | 436,660 | +0.55% | +$38,256.00 | 3.84 | |
| Point72 Asset Management | $6.66M | 0.35 | 417,926 | -15.84% | -$1.25M | 0.01 | |
| JW Asset Management LLC | $6.59M | 0.35 | 413,392 | 0% | +$0 | 2.41 | |
| Bank of America | $6.51M | 0.35 | 408,206 | -45.5% | -$5.43M | <0.01 | |
| UBS | $6.2M | 0.33 | 389,099 | -17.09% | -$1.28M | <0.01 | |
| Ameriprise Financial | $6.08M | 0.32 | 381,350 | -15.67% | -$1.13M | <0.01 | |
| Brandywine Global Investment Management | $5.92M | 0.31 | 371,383 | +108.02% | +$3.07M | 0.04 | |
| RhumbLine Advisers | $4.99M | 0.27 | 312,964 | +8.32% | +$383,243.72 | 0.01 | |
| Legal & General | $4.93M | 0.26 | 309,491 | +7.53% | +$345,515.33 | <0.01 | |
| Moody Aldrich Partners, LLC | $4.8M | 0.26 | 300,951 | -2.26% | -$110,958.34 | 0.82 | |
| Sphera Fund | $4.59M | 0.24 | 288,000 | New | +$4.59M | 0.03 | |
| Hudson Bay Capital Management LP | $4.46M | 0.24 | 280,000 | +75% | +$1.91M | 0.03 | |
| Victory Capital Management Inc | $4.44M | 0.24 | 278,790 | +8.17% | +$335,807.93 | 0.01 | |
| American Century Investments | $4.23M | 0.22 | 265,135 | -71.11% | -$10.4M | <0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.